Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 6Endocrine 3Dermatologic 1CNS 1

Conditions

Brain Neoplasms 7Carcinoma, Renal Cell 4Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neurofibroma, Plexiform 2Glioma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Paraganglioma, Extra-Adrenal 1Neurofibromatosis 1 1Neurofibromatoses 1Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Melanoma 1Lung Neoplasms 1Hepatoblastoma 1

Interventions

Magnetic Resonance Spectroscopy 6Specimen Handling 3Nivolumab 3Fluorodeoxyglucose F18 3Cisplatin 3Cetuximab 3ulixertinib 2tipifarnib 2selpercatinib 2binimetinib 2Trastuzumab 2Surveys and Questionnaires 2Radiotherapy 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2FAPI-46 2Disulfides 2Biopsy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × cabozantinib × CNS × Clear all
NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled 20 charts
CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡